Pratik Shah Trust Amends ARS Pharma Stake

TL;DR

Pratik Shah Trust updated its ARS Pharma filing on 6/11. Big shareholder moving pieces.

AI Summary

The Pratik Shah Living Trust, dated June 15, 2011, has amended its Schedule 13D filing for ARS Pharmaceuticals, Inc. on June 11, 2024. This amendment indicates a change in the trust's beneficial ownership of the company's common stock. The filing does not specify the exact percentage or number of shares now held, but it is an update to their previous disclosure.

Why It Matters

Changes in beneficial ownership filings like this can signal shifts in major shareholder sentiment or strategy, potentially impacting the stock price.

Risk Assessment

Risk Level: medium — Amendments to 13D filings often precede significant market activity or reflect changes in a major holder's strategy, warranting close attention.

Key Players & Entities

• Pratik Shah Living Trust dated June 15, 2011 (company) — Filing entity
• ARS Pharmaceuticals, Inc. (company) — Subject company
• Kathleen Scott (person) — Authorized contact

FAQ

Key Financial Figures

• $0.0001 — 15, 2011, relates to the common stock, $0.0001 par value per share (the Common Stock),

Filing Documents

• d796213dsc13da.htm (SC 13D/A) — 37KB
• 0001193125-24-159314.txt ( ) — 38KB

From the Filing

SC 13D/A 1 d796213dsc13da.htm SC 13D/A SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D U NDER THE S ECURITIES E XCHANGE A CT OF 1934 (Amendment No. 1)* ARS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82835W 108 (CUSIP Number) Kathleen Scott ARS Pharmaceuticals, Inc. 11682 El Camino Real, Suite 120 San Diego, CA 92130 (858) 771-9307 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 4, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ). CUSIP No. 82835W 108 13D 1. Name of Reporting Persons The Pratik Shah Living Trust dated June 15, 2011(1) 2. Check the Appropriate Box if a Member of a Group (see instructions) (a)(b) 3. SEC USE ONLY 4. Source of Funds (see instructions) PF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization United Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 5,219,124 Shares (2) 8. Shared Voting Power 1,332,900 Shares (3) 9. Sole Dispositive Power 5,219,124 Shares (2) 10. Shared Dispositive Power 1,332,900 Shares (3) 11. Aggregate Amount Beneficially Owned by Each Reporting Person 6,552,024 Share s 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions) 13. Percent of Class Represented by Amount in Row 11 6.8 % (4) 14. Type of Reporting Person (see instructions) OO (1) Pratik Shah, Ph.D. is the Trustee of the Reporting Person. (2) Includes 394,570 shares of common stock issuable within 60 days of June 4, 2024 upon the exercise of stock options held by Dr. Shah. (3) These shares of common stock are held by Dr. Shahs spouse. (4) This percentage is calculated based on 96,895,256 shares of common stock outstanding as of May 6, 2024, as reported on the Issuers Quarterly Report on Form 10-Q filed on May 9, 2024. CUSIP No. 82835W 108 13D Explanatory Note: This Amendment No. 1, which amends the Schedule 13D filed with the Securities and Exchange Commission on November 18, 2022, filed on behalf of The Pratik Shah Living Trust dated June 15, 2011, relates to the common stock, $0.0001 par value per share (the Common Stock), of ARS Pharmaceuticals, Inc., a Delaware corporation (the Issuer). Capitalized terms used but not defined herein have the meanings given to such terms in the Original Schedule 13D. Item4. Purpose of Transaction. Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraphs at the end of Item 4: On June 4, 2023, the Reporting Person transferred (i) 1,332,900 shares of Common Stock to The Light Irrevocable Trust #1 (the Light Trust), of which an adult son of Dr. Shah is a beneficiary, (ii) 1,332,900 shares of Common Stock to The Star Irrevocable Trust #1 (the Star Trust), of which an adult son of Dr. Shah is a beneficiary, and (iii) 1,332,900 shares of Common Stock to Dr. Shahs spouse. The transfers to the Light Trust and the Star Trust were each made in exchange for trust assets of equal value under an asset substitution power authorized under the terms of each trust. Dr. Shah has the ability to reacquire these shares within 60 days pursuant to the foregoing asset substitution power, but is not the trustee of either trust. On June 7, 2024, the Reporting Person transferred 1,332,950 shares of Common Stock to The Pratik Shah Trust (the Shah Trust) of which Dr. Shahs spouse is the sole beneficiary. Dr. Shah is the grantor of the Shah Trust but is not the trustee of the Shah Trust. Item5. Interest in Securities of the Issuer. (a)(b) The following information with respect to the ownership of Common Stock of the Issuer by the person filing this Entity Shares Held Directly Sole Voting Power S

View Full Filing

View this SC 13D/A filing on SEC EDGAR